Consolidated statements of income and comprehensive income
(unaudited)
|
Three months ended 31 March |
|
(thousands of €, except per share data) |
2020 |
2019 |
Revenues |
98,173 |
33,047 |
Other income |
8,743 |
7,872 |
Total revenues and other income |
106,916 |
40,919 |
|
|
|
Research and development expenditure |
(116,763) |
(83,195) |
Sales and marketing expenses |
(9,836) |
(1,746) |
General and administrative expenses |
(24,902) |
(9,221) |
Total operating expenses |
(151,501) |
(94,161) |
|
|
|
Operating loss |
(44,585) |
(53,242) |
|
|
|
Fair value re-measurement of warrants |
(20,529) |
- |
Other financial income |
39,722 |
6,999 |
Other financial expenses |
(24,873) |
(2,345) |
|
|
|
Loss before tax |
(50,266) |
(48,588) |
|
|
|
Income taxes |
(336) |
(68) |
|
|
|
Net loss |
(50,601) |
(48,656) |
Net loss attributable to: |
|
|
Owners of the parent |
(50,601) |
(48,656) |
Basic and diluted loss per share |
(0.78) |
(0.89) |
The accompanying notes form an integral part of these condensed consolidated financial statements.
|
Three months ended 31 March |
|
(thousands of €) |
2020 |
2019 |
Net loss |
(50,601) |
(48,656) |
Items that may be reclassified subsequently to profit or loss: |
|
|
Translation differences, arisen from translating foreign activities |
401 |
267 |
Other comprehensive income/loss (-), net of income tax |
401 |
267 |
|
|
|
Total comprehensive loss attributable to: |
|
|
Owners of the parent |
(50,200) |
(48,389) |
The accompanying notes form an integral part of these condensed consolidated financial statements.